Revelation Biosciences reports FY2024 net loss of $15.0M; cash at $6.5M, expects to fund ops into 2025

REVELATION BIOSCIENCES, INC.

Q4 2024 net loss $1.7M ($4.98/share) vs $2.2M ($133.64/share) in Q4 2023.
FY2024 net loss $15.0M ($87.68/share) vs $0.1M ($8.44/share) in FY2023.
Cash and equivalents $6.5M at Dec 31, 2024, down from $12.0M a year ago.
Operating cash burn $18.3M in FY2024 vs $7.3M in FY2023.
Phase 1b PRIME study of Gemini in CKD patients dosing; topline data expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.